EMBL’s European Bioinformatics Institute has grown from a specialist data centre into global research infrastructure for modern biology. Its open data resources, analysis tools and training now support discoveries in health, biodiversity and industry, while its leaders confront challenges around scale, resilience, artificial intelligence and long-term public value today worldwide.
The European Bioinformatics Institute, widely known as EMBL-EBI, occupies a distinctive place in the global life sciences economy. Based at the Wellcome Genome Campus in Hinxton, near Cambridge, it is one of the six sites of the European Molecular Biology Laboratory, an intergovernmental organisation founded in 1974 to advance molecular biology in Europe. EMBL-EBI itself was established in 1994, building on the earlier EMBL Data Library and the growing need to store, organise and share biological sequence information. What began as a response to the rapid growth of molecular data has become a public infrastructure used daily by researchers, clinicians, biotechnology companies, pharmaceutical groups and policy makers. Its role is practical: to make biological data findable, accessible and useful. Through databases, analytical software, training and research, EMBL-EBI enables others to ask better questions about genes, proteins, diseases, organisms and ecosystems. Its history is therefore not simply one of scientific expansion, but of disciplined service delivery in an area where reliability matters.
The institute’s growth has followed the changing shape of biology. In the 1990s, sequencing projects created large volumes of nucleotide data; today, modern research generates information across genomes, metagenomes, protein structures, small molecules, gene expression, disease associations, pathways, samples and literature. EMBL-EBI now maintains a broad range of freely available and regularly updated resources, including services connected with UniProt, Ensembl, the GWAS Catalog, AlphaFold DB and many other specialist platforms. Its search and analysis tools help users move between different types of biological evidence, while submission systems allow scientists to share their own results with the wider community. This open model is central to its purpose. EMBL-EBI’s terms of use avoid additional restrictions on data wherever possible, and its licensing approach aims to support machine-readable reuse. For business leaders, this matters because the value of scientific data is multiplied when it can be combined, checked and reused. The institute’s economic impact report underlines the point, estimating multibillion-pound productivity benefits for public and private sector users.
The challenges facing EMBL-EBI are also the challenges facing data-rich sectors everywhere, though biology adds its own complexity. Data volumes are rising sharply, formats vary, and users range from world-leading computational scientists to laboratory teams needing clear answers quickly. Long-term preservation is another demanding issue: biological data can retain value for decades, but only if infrastructure, funding, standards and expertise remain in place. EMBL-EBI has responded by making resilience part of its operating model, with resource life cycle management, continuity planning, data backup and international partnerships. It also adds value through expert curation and annotation, drawing on biologists who understand the scientific context behind each record. This is increasingly important as automated methods become more powerful. Text mining, machine learning, large language models and other artificial intelligence tools can help scale data processing, but they require careful evaluation, transparent governance and quality control. EMBL-EBI’s approach recognises that automation is most useful when it strengthens, rather than replaces, scientific judgement.
Current priorities show how far the institute’s remit has widened. In human health, its resources help underpin precision medicine, rare disease research, genetic diagnostics and outbreak surveillance. In biodiversity, EMBL-EBI supports initiatives that store and analyse species data for long-term environmental and conservation use. In artificial intelligence, the institute provides the high-quality open data needed to train and validate new tools, while AlphaFold DB demonstrates how public data infrastructure can help turn a major scientific advance into a widely used resource. The organisation also invests in training, recognising that access to tools is not enough without the skills to use them responsibly. Its international workforce and recruitment approach reflect the nature of the field: bioinformatics depends on scientists, engineers, curators, trainers and operations specialists working across borders. For industry, EMBL-EBI is not a conventional supplier, but a trusted public partner whose resources reduce duplication, accelerate research and create common ground between academic discovery and commercial development.
EMBL-EBI’s history shows that durable public infrastructure can strengthen science, industry, healthcare, and society worldwide. Its response to modern data pressures combines openness, expert curation, resilient systems, and international cooperation. For business leaders, the lesson is clear: trusted information creates measurable value at scale globally. As biology becomes more computational, EMBL-EBI remains a practical partner for discovery, application, and innovation. Its continuing impact will depend on sustaining skills, funding, standards, and public confidence over time.
